Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Fish and Richardson
Baxter
Deloitte
US Army
Healthtrust
Cipla
Argus Health

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,687,052

« Back to Dashboard

Which drugs does patent 7,687,052 protect, and when does it expire?

Patent 7,687,052 protects AMYVID and is included in one NDA.

This patent has thirty-seven patent family members in thirty-one countries.
Summary for Patent: 7,687,052
Title:Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Abstract: This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
Inventor(s): Kung; Hank F. (Winnewood, PA), Kung; Mei-Ping (Winnewood, PA)
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:11/727,401
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,687,052

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-001 Apr 6, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-002 Apr 6, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-003 Apr 6, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,687,052

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,506,929 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques ➤ Try a Free Trial
8,840,866 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,687,052

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 539060 ➤ Try a Free Trial
Australia 2007243712 ➤ Try a Free Trial
Brazil PI0710225 ➤ Try a Free Trial
Canada 2644530 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Federal Trade Commission
Accenture
Chinese Patent Office
Cipla
Baxter
Express Scripts
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.